Eslicarbazepine Acetate
Brand name: Aptiom
Rank #252 of 500 drugs by total cost
$51.1M
Total Cost
31,472
Total Claims
$51.1M
Total Cost
1,123
Prescribers
$1,622
Cost per Claim
601
Beneficiaries
34,153
30-Day Fills
$45K
Avg Cost/Provider
28
Avg Claims/Provider
About Eslicarbazepine Acetate
Eslicarbazepine Acetate (sold as Aptiom) was prescribed 31,472 times by 1,123 Medicare Part D providers in 2023, costing the program $51.1M. At $1,622 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 249 | Nifedipine (Nifedipine Er) | $51.2M | 1,249,866 |
| 250 | Clobetasol Propionate (Clobetasol Propionate) | $51.2M | 758,575 |
| 251 | Sodium,calcium,mag,pot Oxybate (Xywav) | $51.1M | 3,234 |
| 252 | Eslicarbazepine Acetate (Aptiom) | $51.1M | 31,472 |
| 253 | Risdiplam (Evrysdi) | $51.1M | 1,891 |
| 254 | Amikacin Liposomal/Neb.Accessr (Arikayce) | $50.5M | 3,394 |
| 255 | Diclofenac Epolamine (Licart) | $50.5M | 72,299 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology